Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals

BACKGROUND AND STUDY AIMS: Currently, there is no therapy approved for COVID-19. We evaluated the efficacy and safety of sofosbuvir/ledipasvir and nitazoxanide for the treatment of patients with COVID-19 infection. PATIENTS AND METHODS: A multicenter, open-label randomized controlled trial included...

Descripción completa

Detalles Bibliográficos
Autores principales: Medhat, Mohamed A., El-Kassas, Mohamed, Karam-Allah, Haidi, Al Shafie, Ahmed, Abd-Elsalam, Sherief, Moustafa, Ehab, Hassany, Sahar M., Salama, Marwa, Abd Elghafar, Mohamed S., Sayed, Hamdy, Badr, Mohamed, Kamal, Dalia T., Shamseldeen, Ahmed, Ossimi, Ashima'a, Moaz, Inas, El-deen Esmael, Hossam, Ezz Eldin, Azza M., Ezzat, Sameera, Abdelghaffar, Hossam, Abdelghaffar, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116423/
https://www.ncbi.nlm.nih.gov/pubmed/35690556
http://dx.doi.org/10.1016/j.ajg.2022.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116423/
https://www.ncbi.nlm.nih.gov/pubmed/35690556
http://dx.doi.org/10.1016/j.ajg.2022.04.005

Ejemplares similares